Skip to main content
Premium Trial:

Request an Annual Quote

Astex of Britain Raises $8 Million

NEW YORK, Dec. 17 – British structural genomics company Astex Technology said Monday it raised 5.7 million pounds ($8.1 million) in its second round of private financing this year. 

Previous investors in Astex, including Abingworth, Advent International, Alta Partners, GIMV, and Oxford Bioscience Partners, participated in the round. 

The Cambridge-based company said it would use the funds to develop its structure-based drug discovery technologies.

“These funds put us in a strong position to rapidly progress the novel drug discovery approaches being developed at Astex," Timothy Haines, CEO of Astex said in a statement.  

Astex uses high throughput X-ray crystallography to determine protein structures. In addition to its HTX platform, uses structure determination, bioinformatics, and computational and medicinal chemistry to discovery new drugs. 

Astex has research agreements with Janssen Research Foundation and AstraZeneca.

So far this year Astex has raised 28.4 million pounds.

 

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.